AptaBio Therapeutics Inc. (KOSDAQ:293780)

AptaBio Therapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	14,712	16,079	25,542	25,016	1,989
Short-Term Investments	1,014	1,112	1,020	19,000	15,026
Trading Asset Securities	-	-	4,954	8,869	-
Cash & Short-Term Investments	15,725	17,190	31,515	52,885	17,015
Cash Growth	-30.33%	-45.45%	-40.41%	210.81%	-
Accounts Receivable	681.31	591.25	893.71	-	-
Other Receivables	179.19	104.64	238.05	366.31	224.46
Receivables	944.21	3,195	1,435	2,659	3,047
Inventory	598.13	612.76	224.87	-	-
Prepaid Expenses	59.88	35.28	208.43	176.31	88.23
Other Current Assets	5,251	4,318	1,552	1,754	268.93
Total Current Assets	22,579	25,351	34,935	57,474	20,419
Property, Plant & Equipment	6,145	5,861	4,962	5,129	5,848
Long-Term Investments	21,336	26,298	30,986	23,779	27,885
Goodwill	1,020	1,020	-	-	-
Other Intangible Assets	26.3	32.87	39.35	61.09	37.83
Other Long-Term Assets	888.23	1,464	3,611	3,675	1,924
Total Assets	54,395	60,027	77,434	92,519	56,114

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Accounts Payable	84.09	30.42	1.87	-	-
Accrued Expenses	580.61	813.24	609.79	337.19	455.54
Short-Term Debt	4,816	4,234	7,244	-	-
Current Portion of Leases	85.57	157.86	154.6	131.08	109.73
Current Income Taxes Payable	-	-	-	1.48	-
Other Current Liabilities	3,328	4,480	11,529	348.2	474.75
Total Current Liabilities	8,895	9,715	19,540	817.95	1,040
Long-Term Debt	-	-	-	13,569	-
Long-Term Leases	11.4	30.51	122.01	233.45	256.3
Pension & Post-Retirement Benefits	3,193	3,006	3,503	3,011	2,393
Other Long-Term Liabilities	95.03	90.58	71.4	13,524	54.58
Total Liabilities	12,195	12,842	23,237	31,156	3,744

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Common Stock	14,047	14,047	13,441	11,149	11,149
Additional Paid-In Capital	157,922	157,922	149,733	129,712	109,025
Retained Earnings	-131,604	-126,278	-110,112	-80,713	-68,473
Comprehensive Income & Other	1,836	1,494	1,135	696.37	668.63
Total Common Equity	42,200	47,185	54,197	60,845	52,370
Shareholders' Equity	42,200	47,185	54,197	61,363	52,370
Total Liabilities & Equity	54,395	60,027	77,434	92,519	56,114

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Total Debt	4,913	4,422	7,521	13,934	366.03
Net Cash (Debt)	10,812	12,768	23,994	38,951	16,649
Net Cash Growth	-23.18%	-46.79%	-38.40%	133.95%	-
Net Cash Per Share	393.43	474.51	1019.29	1746.78	746.98
Filing Date Shares Outstanding	27.89	28.09	26.88	22.3	22.3
Total Common Shares Outstanding	27.89	28.09	26.88	23.34	22.3
Working Capital	13,684	15,636	15,395	56,656	19,379
Book Value Per Share	1513.24	1679.56	2016.16	2607.28	2348.53
Tangible Book Value	41,154	46,131	54,158	60,784	52,332
Tangible Book Value Per Share	1475.71	1642.07	2014.69	2604.66	2346.83
Land	2,251	2,115	1,787	1,787	1,922
Buildings	4,490	4,123	3,215	3,046	3,388
Machinery	1,347	1,337	1,268	1,196	1,101

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 3, 2026

Data Sources Report a data error